



## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	628	((546/347) or (514/358)).CCLS.	US-PGPUB; USPAT	OR	OFF	2007/03/14 17:56
L2	34	1 and cetylpyridinium and salt	US-PGPUB; USPAT	OR	OFF	2007/03/14 17:57
L3	39	(pifferi adj giorgio.inv.)	US-PGPUB; USPAT	OR	OFF	2007/03/14 17:57



```

chain nodes :
  7 15 16 19 21 22 23 24
ring nodes :
  1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
  5-7 7-10 19-24 21-23 21-22 21-24
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
  5-7 7-10 21-23 21-22
exact bonds :
  19-24 21-24
normalized bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
isolated ring systems :
  containing 1 : 8 :

```

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom
 10:Atom 11:Atom 12:Atom 13:Atom 15:CLASS 16:CLASS 17:Atom 18:Atom
 19:CLASS 20:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS

```

10544224

=> d his

(FILE 'HOME' ENTERED AT 13:39:35 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 14 MAR 2007  
E DICLOFENAC/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:39:57 ON 14 MAR 2007

L2 4481 S L1

L3 519 S L2 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:40:17 ON 14 MAR 2007  
E CETYLPYRIDINIUM/CN

L4 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:40:44 ON 14 MAR 2007

L5 1 S L4 AND L1

L6 4481 S L1

L7 920 S L4

L8 1 S L6 AND L7

L9 20 S L1 AND CETYLPYRIDINIUM?

L10 10 S L9 AND SALT?

L11 2 S L1 () SALT?

FILE 'CAOLD' ENTERED AT 13:44:16 ON 14 MAR 2007

L12 0 S L1 AND CETYLPYRIDINIUM?

L13 0 S L1 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:44:38 ON 14 MAR 2007  
STRUCTURE UPLOADED

L14 32 S L14

L16 1099 S L14 FULL

FILE 'HCAPLUS' ENTERED AT 13:46:47 ON 14 MAR 2007

L17 30 S L16 AND CETYLPYRIDINIUM?

L18 14 S L17 () SALT?

L19 16 S L17 NOT L18

FILE 'CAOLD' ENTERED AT 13:50:10 ON 14 MAR 2007

=> s l16 and l4

0 L16

0 L4

L20 0 L16 AND L4

=> s l16 and salt

0 L16

14458 SALT

30899 SALTS

44506 SALT

(SALT OR SALTS)

L21 0 L16 AND SALT

=>

Updated Search

10544224

=> d his

(FILE 'HOME' ENTERED AT 13:39:35 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 14 MAR 2007  
E DICLOFENAC/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:39:57 ON 14 MAR 2007

L2 4481 S L1

L3 519 S L2 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:40:17 ON 14 MAR 2007  
E CETYLPYRIDINIUM/CN

L4 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:40:44 ON 14 MAR 2007

L5 1 S L4 AND L1

L6 4481 S L1

L7 920 S L4

L8 1 S L6 AND L7

L9 20 S L1 AND CETYLPYRIDINIUM?

L10 10 S L9 AND SALT?

L11 2 S L1 () SALT?

FILE 'CAOLD' ENTERED AT 13:44:16 ON 14 MAR 2007

L12 0 S L1 AND CETYLPYRIDINIUM?

L13 0 S L1 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:44:38 ON 14 MAR 2007

L14 STRUCTURE UPLOADED

L15 32 S L14

L16 1099 S L14 FULL

FILE 'HCAPLUS' ENTERED AT 13:46:47 ON 14 MAR 2007

L17 30 S L16 AND CETYLPYRIDINIUM?

L18 14 S L17 () SALT?

L19 16 S L17 NOT L18

FILE 'CAOLD' ENTERED AT 13:50:10 ON 14 MAR 2007

=> s l16 and l4

0 L16

0 L4

L20 0 L16 AND L4

=> s l16 and salt

0 L16

14458 SALT

30899 SALTS

44506 SALT

(SALT OR SALTS)

L21 0 L16 AND SALT

=>

Updated Search

10544224

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspal612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	30	Feb 26	MEDLINE reloaded with enhancements
NEWS	31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS	32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

Updated Search

10544224

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:39:35 ON 14 MAR 2007

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 14 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6  
DICTIONARY FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> e diclofenac/cn  
E1 1 DICLOCYMET-TIADINIL MIXT./CN  
E2 1 DICLOFEN SR 100/CN  
E3 1 --> DICLOFENAC/CN  
E4 1 DICLOFENAC 1-(2-HYDROXYETHYL)PYRROLIDINE SALT/CN  
E5 1 DICLOFENAC 2-(METHANESULFONYL)ETHYL ESTER/CN  
E6 1 DICLOFENAC 3-HYDROXYPROPYL ESTER/CN

Updated Search

10544224

E7 1 DICLOFENAC 4'-HYDROXYLASE/CN  
E8 1 DICLOFENAC 4'-MONOOXYGENASE/CN  
E9 1 DICLOFENAC 4-((METHANESULFONYL)AMINO)BUTYL ESTER/CN  
E10 1 DICLOFENAC 4-((TOLUENESULFONYL)AMINO)BUTYL ESTER/CN  
E11 1 DICLOFENAC ACID/CN  
E12 1 DICLOFENAC ALLYL ESTER/CN

=> s e3

L1 1 DICLOFENAC/CN

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 15307-86-5 REGISTRY

ED Entered STN: 16 Nov 1984

CN Benzeacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Acetic acid, [o-(2,6-dichloroanilino)phenyl]- (8CI)

OTHER NAMES:

CN 2-(2,6-Dichloroanilino)phenylacetic acid

CN 2-(2,6-Dichlorophenylamino)phenylacetic acid

CN 2-[(2,6-Dichlorophenyl)amino]benzeacetic acid

CN Dichlofenac

CN Diclofenac

CN Diclofenac acid

CN Diclofenamic acid

CN Diclomelan

CN Dicloreuma

CN N-(2,6-Dichlorophenyl)-o-aminophenylacetic acid

CN Pennsaid

CN Transfenac

CN [o-(2,6-Dichloroanilino)phenyl]acetic acid

DR 76595-40-9, 87180-41-4

MF C14 H11 Cl2 N O2


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4452 REFERENCES IN FILE CA (1907 TO DATE)

146 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

Updated Search

10544224

4481 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file hcaplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.35	7.56

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 13:39:57 ON 14 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Mar 2007 VOL 146 ISS 12  
FILE LAST UPDATED: 13 Mar 2007 (20070313/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 13:39:35 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 14 MAR 2007  
E DICLOFENAC/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:39:57 ON 14 MAR 2007

=> s l1

L2 4481 L1

=> s l2 and salt?

1204558 SALT?

L3 519 L2 AND SALT?

=> file reg  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.60	10.16

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:40:17 ON 14 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Updated Search

10544224

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6  
DICTIONARY FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> e cetylpyridinium/cn

E1	1	CETYLOXYMETHYLPYRIDINIUM CHLORIDE/CN
E2	1	CETYLOXYTRIMETHYLSILANE/CN
E3	1 -->	CETYLPYRIDINIUM/CN
E4	1	CETYLPYRIDINIUM 2,4,5-TRINITROIMIDAZOLE/CN
E5	1	CETYLPYRIDINIUM 2-NAPHTHOLATE/CN
E6	1	CETYLPYRIDINIUM 3,5-DINITROPYRAZOLE/CN
E7	1	CETYLPYRIDINIUM 4,5-DINITROIMIDAZOLE/CN
E8	1	CETYLPYRIDINIUM 5-NITROTETRAZOLE/CN
E9	1	CETYLPYRIDINIUM ACETATE/CN
E10	1	CETYLPYRIDINIUM ALGINATE/CN
E11	1	CETYLPYRIDINIUM AMYLXANTHATE/CN
E12	1	CETYLPYRIDINIUM BENZENESULFONATE/CN

=> s e3

L4 1 CETYLPYRIDINIUM/CN

=> d 14

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 7773-52-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN Pyridinium, 1-hexadecyl- (8CI, 9CI) (CA INDEX NAME)

OTHER NAMES:

CN Ceepryn

CN Cetylpyridinium

CN Hexadecylpyridinium

CN N-Hexadecylpyridinium

DR 85040-60-4, 87980-44-7, 203063-55-2


MF C21 H38 N

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, EMBASE, GMELIN\*, IFICDB, IFIPAT, IFIUDB, MEDLINE, PROMT, RTECS\*, TOXCENTER, TULSA, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Updated Search

10544224



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

917 REFERENCES IN FILE CA (1907 TO DATE)  
329 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
920 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 13:39:35 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 14 MAR 2007  
E DICLOFENAC/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:39:57 ON 14 MAR 2007

L2 4481 S L1

L3 519 S L2 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:40:17 ON 14 MAR 2007  
E CETYLPIRIDINIUM/CN

L4 1 S E3

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.35	17.51

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 13:40:44 ON 14 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Mar 2007 VOL 146 ISS 12  
FILE LAST UPDATED: 13 Mar 2007 (20070313/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Updated Search

10544224

=> d his

(FILE 'HOME' ENTERED AT 13:39:35 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 14 MAR 2007  
E DICLOFENAC/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:39:57 ON 14 MAR 2007

L2 4481 S L1

L3 519 S L2 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:40:17 ON 14 MAR 2007  
E CETYLPYRIDINIUM/CN

L4 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:40:44 ON 14 MAR 2007

=> s l4 and l1

920 L4

4481 L1

L5 1 L4 AND L1

=> s l1

L6 4481 L1

=> s l4

L7 920 L4

=> s l6 and l7

L8 1 L6 AND L7

=> d l8, ibib abs hitstr, 1

L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:412720 HCAPLUS

DOCUMENT NUMBER: 140:395547

TITLE: Medicated comestibles

INVENTOR(S): Conyers, Leigh

PATENT ASSIGNEE(S): SSL International PLC, UK

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004040992	A1	20040521	WO 2003-GB4823	20031106
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,			


Updated Search

10544224

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
AU 2003283533 A1 20040607 AU 2003-283533 20031106  
PRIORITY APPLN. INFO.: GB 2002-25827 A 20021106  
WO 2003-GB4823 W 20031106  
AB A chewable medicated comestible is made by mixing a pharmaceutically active ingredient, water and a substrate. The substrate has confectionery and binding properties and the mixing process produces a malleable solid confection which can be divided into discrete dosed units in the form of chewable tablets. The substrate may be a particular sugar. A chewable tablet contained modified starch 50, water 7, sorbitol 8, starch 1.5, milk protein 1, gelatin 1.2, water 5, glycerol 5, propylene glycol 2, titanium dioxide 1, vegetable fat 6, omeprazole 0.25, lactose 7.05, and maltodextrin 10%.  
IT 7773-52-6, Cetylpyridinium 15307-86-5, Diclofenac  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medicated comestibles)  
RN 7773-52-6 HCAPLUS  
CN Pyridinium, 1-hexadecyl- (8CI, 9CI) (CA INDEX NAME)



RN 15307-86-5 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 13:39:35 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 14 MAR 2007

E DICLOFENAC/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:39:57 ON 14 MAR 2007

L2 4481 S L1

L3 519 S L2 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:40:17 ON 14 MAR 2007

E CETYLPYRIDINIUM/CN

L4 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:40:44 ON 14 MAR 2007

L5 1 S L4 AND L1

L6 4481 S L1

Updated Search

10544224

L7 920 S L4  
L8 1 S L6 AND L7

=> s l1 and cetylpyridinium?

4481 L1  
6460 CETYLPYRIDINIUM?  
L9 20 L1 AND CETYLPYRIDINIUM?

=> s l9 and salt?

1204558 SALT?  
L10 10 L9 AND SALT?

=> d l10, ibib abs hitstr, 1-10

L10 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:443573 HCAPLUS

DOCUMENT NUMBER: 144:475020

TITLE: Device and method for delivering an oral care agent  
form a hydrophilic polymer layer

INVENTOR(S): Faasse, Adrian L.; Klemm, Steven Richard; Groeneweg,  
Glen Edward; Thelen, Alan Gene

PATENT ASSIGNEE(S): Ranir/Dcp Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 24 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006099550	A1	20060511	US 2004-985709	20041110
WO 2006052593	A2	20060518	WO 2005-US39632	20051102
WO 2006052593	A3	20070104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-985709 A 20041110

AB A delivery device for oral care agent, especially a tooth whitening agent, is provided which comprises a permanently deformable waxy backing layer, an oral care layer made of a hydrophilic polymer, and a non-woven binding material with a first part that is substantially invested in the oral care layer and a second part that is substantially invested in the backing layer. The device is sized to fit over a plurality of teeth in an upper or lower dental arch of a subject. The oral care layer comprises at least one oral care agent and at least one hydrophilic polymer. When hydrated, the oral care layer has an adhesiveness relative to the surface of a user's teeth that is sufficient to retain the device on the user's teeth when placed thereon. The device can also have an oral care agent which is activated on hydration of the oral care layer, or an oral care layer which

Updated Search

10544224

releases the oral care agent over time. For example, a system for delivering a tooth whitening agent was constructed comprising (i) a backing layer (thickness of about 0.38 mm) composed of microcryst. wax 50%, paraffin wax 15% and a hydrocarbon resin (Escorez 5380) 35%, (ii) a non-woven binding layer (thickness of about 0.152 mm) composed of a layer of spun bonded polypropylene (Tyvar) invested in the backing layer, and (iii) an oral care layer containing Kollidone 90 58%, Carbowax 400 30%, and Eudragit L100/55 12%. The oral care agent (an aqueous hydrogen peroxide

solution

equivalent to 3-10% of oral care layer) was absorbed by the oral care layer, Delnet nonwoven polyolefin fabric scrim was placed over the aqueous hydrogen peroxide solution printed onto the nonwoven, followed by laminating the oral care layer to the binding material. After the backing and oral care layers were formed with the binding material, devices of were cut to the desired size and shape and vacuum formed on a forming die. The overall thickness of the device was about 0.51 to 0.61 mm.


IT 15307-86-5, Diclofenac

RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(multilayered device for delivering oral care agents form hydrophilic polymer layer)

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



L10 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:472002 HCAPLUS

DOCUMENT NUMBER: 143:13359

TITLE: Nanoparticle compositions comprising antibodies for targeted delivery

INVENTOR(S): Liversidge, Elaine; Cunningham, James

PATENT ASSIGNEE(S): Elan Pharma International Ltd., Ire.

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049091	A2	20050602	WO 2004-US37246	20041109
WO 2005049091	A3	20061109		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			

Updated Search

10544224

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG

US 2005147664 A1 20050707 US 2004-979792 20041103  
CA 2545856 A1 20050602 CA 2004-2545856 20041109  
EP 1689442 A2 20060816 EP 2004-810555 20041109

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,  
HR, IS, YU

PRIORITY APPLN. INFO.:

US 2003-519251P P 20031113  
WO 2004-US37246 W 20041109


AB The present invention is directed to compns. of one or more  
nanoparticulate active agents, at least one PEG-derivatized surface  
stabilizer, and at least one antibody or fragment thereof, and methods of  
using such compns. for targeting delivery of the one or more active agents  
to a desired site. The one or more active agents preferably have a  
particle size of  $\leq 2 \mu$ . The targeted delivery can be used, e.g.,  
for disease diagnosis, imaging, or drug delivery. Thud, WIN-68209  
particles wee stabilized by PEG-DSPE stabilizer.

IT 15307-86-5, Diclofenac

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nanoparticle compns. comprising antibodies for targeted delivery)

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



L10 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:120587 HCAPLUS

DOCUMENT NUMBER: 140:157476

TITLE: Use of a compound in providing refreshedness on waking  
and a method for the treatment of grogginess therewith

INVENTOR(S): Sunderraj, Palaniswamy; Jones, Huw; Shephard, Adrian

PATENT ASSIGNEE(S): The Boots Company Plc, UK

SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S.  
Ser. No. 305,354.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004029927	A1	20040212	US 2003-448455	20030530
US 2003134878	A1	20030717	US 2002-305354	20021127
GB 2383537	A	20030702	GB 2002-28045	20021202
GB 2383537	B	20031210		
CN 1617723	A	20050518	CN 2002-827625	20021202
ZA 2004004172	A	20050901	ZA 2004-4172	20040527

Updated Search


10544224

US 2007015800 A1 20070118 US 2005-303019 20051216  
PRIORITY APPLN. INFO.: GB 2001-28674 A 20011130  
US 2002-305354 A2 20021127


AB There is disclosed the use of triprolidine for enabling an individual to wake refreshed after sleep and the method of treating such an individual with triprolidine. The triprolidine is administered shortly before a person wishes to fall asleep, preferably orally and most commonly in the form of a tablet containing less than 5 mg, e.g. 0.1 mg, 1.25 mg or 2.5 mg, of the active ingredient. The triprolidine is also effective in enabling an individual to sleep more easily. There is also disclosed such uses of, and methods of treating with, consumable films comprising triprolidine, and triprolidine in combination with at least one further active pharmaceutical agent, and consumable films comprising triprolidine in combination with at least one further active pharmaceutical agent.

IT 15307-86-5, Diclofenac 15307-86-5D, Diclofenac,  
salts or hydrates  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(as further active agent; triprolidine and comps. in providing  
refreshedness on waking and in treatment of grogginess)

RN 15307-86-5 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



RN 15307-86-5 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



L10 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:11043 HCAPLUS  
DOCUMENT NUMBER: 140:82330  
TITLE: Body protection article having a gelatinous material  
with a therapeutic additive  
INVENTOR(S): Gould, Robert L.; Whelan, Ian Peter  
PATENT ASSIGNEE(S): Silipos Inc., USA  
SOURCE: U.S., 11 pp., Cont.-in-part of U.S. 6,117,119.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

Updated Search

10544224


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6673054	B1	20040106	US 2000-654581	20000901
US 6117119	A	20000912	US 1998-143282	19980828
PRIORITY APPLN. INFO.:			US 1998-143282	A2 19980828

AB The present invention is directed to a vitamin additive such as Vitamin A, B12, C, D, E, incorporated into the thermoplastic material of a sock, glove or like body protection article. The thermoplastic material is preferably a block copolymer such as SEBS, SEPS and SEEPS copolymer. Addnl., the thermoplastic material can include natural oils such as grape seed oil, avocado oil, jojoba oil, canola oil, ceramides, aloe and olive oil. Such materials impart beneficial properties to the skin including reducing scar tissue from burned skin and skin healing from a surgical procedure by maintaining the skin in a moist and lubricated state.

IT 15307-86-5, Diclofenac  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (body protection article consisting of gelatinous material with therapeutic additive)

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:42092 HCAPLUS

DOCUMENT NUMBER: 138:112443

TITLE: Tablet compositions for poorly-compressible pharmaceuticals

INVENTOR(S): Matharu, Amol Singh; Patel, Mahendra R.

PATENT ASSIGNEE(S): Geneva Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 20 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004009	A1	20030116	WO 2002-US20323	20020627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				

Updated Search

10544224

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
US 2003021841 A1 20030130 US 2002-183881 20020627  
PRIORITY APPLN. INFO.: US 2001-302613P P 20010702  
AB The present invention relates to a process for preparing tablet dosage forms of poorly-compressible pharmaceuticals and to tablet dosage forms. The process is especially useful for preparing tablets of the poorly-compressible drug metformin-HCl. Thus, tablets contained metformin-HCl 500, HPMC 320, stearyl alc. 200, and Mg stearate mg/unit.  
IT 15307-86-5, Diclofenac  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tablet compns. for poorly-compressible pharmaceuticals)  
RN 15307-86-5 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:1215 HCAPLUS

DOCUMENT NUMBER: 138:61315

TITLE: Controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers

INVENTOR(S): Chhabra, Harinderpal; Sarkar, Shyamal K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 23 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6500459	B1	20021231	US 1999-358732	19990721
CA 2314298	A1	20010121	CA 2000-2314298	20000721
PRIORITY APPLN. INFO.:			US 1999-358732	A 19990721


AB A pharmaceutical composition for controlled onset and sustained release of an active ingredient, comprises: (i) a core comprising: (a) an active ingredient; (b) a hydrophilic carrier; (c) a hydrodynamic diffusion enhancer; and optionally (d) conventional excipients selected from the group consisting of binders, fillers and lubricants and combinations thereof; and (ii) a functional coating membrane surrounding the core. Thus, 240 g verapamil-HCl was sieved through a mesh sieve and blended with 150 g E50 premium HPMC. To this blend was added 270.0 g croscarmellose sodium and mixed for 15 min. This blend was granulated with PVP K-29/32 solution in iso-PrOH (30% weight/weight). The wet mass obtained in the above step was dried at 60° for 3 h. After drying, the granules were passed a

Updated Search

10544224

mesh sieve. The granules were then mixed with 2.5 g of Magnesium Stearate and 15 g of Stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. The granules were then mixed with 2.5 g of Mg stearate and 15 g of stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. These tablets were then coated by using a perforated coating pan. A seal coating membrane was applied on the surface of tablets to achieve a weight gain of 1.66% of the weight of the core. The seal coating dispersion of Opadry Clear in water at 10% was sprayed on to the surface of the tablets by using a perforated coating pan.

IT 15307-86-5, Diclofenac  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)  
 RN 15307-86-5 HCAPLUS  
 CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:31308 HCAPLUS

DOCUMENT NUMBER: 134:91147

TITLE: A method for the improvement of transport across adaptable semi-permeable barriers

INVENTOR(S): Cevc, Gregor

PATENT ASSIGNEE(S): Idea Innovative Dermale Applikationen G.m.b.H., Germany

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001962	A1	20010111	WO 1999-EP4659	19990705
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9954096	A	20010122	AU 1999-54096	19990705
CA 2375157	A1	20010111	CA 2000-2375157	20000705
WO 2001001963	A1	20010111	WO 2000-EP6367	20000705

Updated Search

10544224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CE, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1189598 A1 20020327 EP 2000-947939 20000705

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

HU 200201454 A2 20021228 HU 2002-1454 20000705

JP 2003503442 T 20030128 JP 2001-507458 20000705

EE 200200008 A 20030415 EE 2002-8 20000705

AU 779765 B2 20050210 AU 2000-61557 20000705

RU 2260445 C2 20050920 RU 2002-101651 20000705

HR 2001000881 A1 20030831 HR 2001-881 20011127

IN 2001DN01133 A 20050311 IN 2001-DN1133 20011206

NO 2002000032 A 20020305 NO 2002-32 20020104

US 2003099694 A1 20030529 US 2002-37480 20020104

US 2005123897 A1 20050609 US 2004-984450 20041108

PRIORITY APPLN. INFO.: WO 1999-EP4659 A 19990705

WO 2000-EP6367 W 20000705

US 2002-37480 A1 20020104


AB The invention relates to a method, a kit and a device for controlling the flux of penetrants across an adaptable semi-permeable porous barrier, the method comprising the steps of: preparing a formulation by suspending or dispersing said penetrants in a polar liquid in the form of fluid droplets surrounded by a membrane-like coating of one or several layers, said coating comprising at least two kinds of forms of amphiphilic substances with a tendency to aggregate; said penetrants being able to transport agents through the pores of said barrier or to enable agent permeation through the pores of said barrier after penetrants have entered the pores, selecting a dose amount of said penetrants to be applied on a predetd. area of said barrier to control the flux of said penetrants across said barrier, and applying the selected dose amount of said formulation containing said penetrants onto said area of said porous barrier. Highly adaptable complex droplets (ultradeformable vesicles or Transfersomes) were prepared containing soybean phosphatidylcholine, Na cholate, 3H-labeled DPPC and phosphate buffer.

IT 15307-86-5, Diclofenac

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (improvement of transport across adaptable semi-permeable barriers)

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Updated Search

10544224

L10 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:456858 HCAPLUS  
DOCUMENT NUMBER: 133:94512  
TITLE: Improved formulation for topical non-invasive application in vivo  
INVENTOR(S): Cevc, Gregor  
PATENT ASSIGNEE(S): Idea Innovative Dermale Applikationen G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 73 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038653	A1	20000706	WO 1998-EP8421	19981223
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356080	A1	20000706	CA 1998-2356080	19981223
AU 9925137	A	20000731	AU 1999-25137	19981223
AU 770803	B2	20040304		
EP 1140021	A1	20011010	EP 1998-966846	19981223
EP 1140021	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9816113	A	20011023	BR 1998-16113	19981223
JP 2002533379	T	20021008	JP 2000-590607	19981223
EE 200100342	A	20021015	EE 2001-342	19981223
RU 2207844	C2	20030710	RU 2001-120008	19981223
AT 272391	T	20040815	AT 1998-966846	19981223
ES 2226203	T3	20050316	ES 1998-966846	19981223
HR 2001000309	A1	20020630	HR 2001-309	20010502
HR 20010309	B1	20050630		
NO 2001003164	A	20010822	NO 2001-3164	20010622
US 2002064524	A1	20020530	US 2001-887493	20010622
US 7175850	B2	20070213		
HK 1040629	A1	20050128	HK 2002-102230	20020323

PRIORITY APPLN. INFO.: WO 1998-EP8421 A 19981223

OTHER SOURCE(S): MARPAT 133:94512


AB A formulation comprises mol. arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of the pores is smaller than the average penetrant diameter, provided that

the penetrants can transport agents or cause permeation through the pores after penetrants have entered pores. The formulation comprises at least 1 consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over is enabled. The formulation also contains 1 antioxidant in an amount that reduces the increase of oxidation index to <100% per 6 mo and/or at least 1 microbicide in an amount that reduces the bacterial count of 1 million germs added/g of total mass of the formulation to <100 in the case of aerobic bacteria, to <10 in the case of

10544224

entero-bacteria, and to <1 in the case of Pseudomonas aeruginosa or Staphylococcus aureus, after a period of 4 days. Thus, a composition contained soybean phosphatidylcholine 347, Tween-80 623, sodium dodecyl sulfate 30, benzyl alc. 50, clobetasol 17-propionate 25 and pH 6.5 50 mM phosphate buffer 9000 mg.

IT 15307-86-5, Diclofenac  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (penetrating formulation for topical non-invasive application in vivo)  
 RN 15307-86-5 HCAPLUS  
 CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1999:172578 HCAPLUS  
 DOCUMENT NUMBER: 130:227723  
 TITLE: In situ formation of bioadhesive polymeric material  
 INVENTOR(S): Dettmar, Peter William; Jolliffe, Ian Gordon; Skaugrud, Oyvind  
 PATENT ASSIGNEE(S): Reckitt & Colman Products Limited, UK  
 SOURCE: PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909962	A1	19990304	WO 1998-GB2410	19980810
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2328443	A	19990224	GB 1998-17093	19980807
GB 2328443	B	20010905		
CA 2301165	A1	19990304	CA 1998-2301165	19980810
CA 2301165	C	20070109		
AU 9887389	A	19990316	AU 1998-87389	19980810
AU 737714	B2	20010830		
EP 1007015	A1	20000614	EP 1998-938785	19980810
EP 1007015	B1	20030709		
R: AT, CH, DE, ES, FR, GB, GR, IT, LI, SE				
BR 9811245	A	20000718	BR 1998-11245	19980810


Updated Search

10544224

HU 200003602	A2	20010328	HU 2000-3602	19980810
JP 2001513549	T	20010904	JP 2000-507353	19980810
AT 244562	T	20030715	AT 1998-938785	19980810
ES 2198062	T3	20040116	ES 1998-938785	19980810
PL 192463	B1	20061031	PL 1998-338701	19980810
IN 1998MA01833	A	20050304	IN 1998-MA1833	19980813
ZA 9807516	A	19990222	ZA 1998-7516	19980820
MX 200001818	A	20001026	MX 2000-1818	20000221
US 6391294	B1	20020521	US 2000-485771	20000412
PRIORITY APPLN. INFO.:			GB 1997-17626	A 19970821
			GB 1997-17627	A 19970821
			WO 1998-GB2410	W 19980810

AB The invention provides a pharmaceutically acceptable polymeric material formed in situ at a body surface and a process for the preparation of material. The polymeric material is formed by applying an anionic polymer and a cationic polymer to the surface in the presence of water. Thus, an anionic solution contained sodium alginate 2, and methylparaben (preservative) 0.1 g, flavors, sweeteners, and colors q.s. and water to 100 mL. A cationic solution contained chitosan chloride (Seacure CL 211) 0.4 and methylparaben (preservative) 0.1 g, flavors, sweeteners, colors q.s. and water to 100 mL. Dissolve the Me paraben, flavors, sweeteners and colors in the water. Between 0.2 and 1 mL of each solution may be sprayed simultaneously onto the back of the throat to form a soothing protective film. This film is of particular benefit to those suffering from a sore throat.

IT 15307-86-5, Diclofenac  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (in situ formation of bioadhesive polymeric material)  
 RN 15307-86-5 HCAPLUS  
 CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1997:310769 HCAPLUS  
 DOCUMENT NUMBER: 126:297668  
 TITLE: Ophthalmic compositions containing cyclodextrins and quaternary ammonium compounds  
 INVENTOR(S): Kis, Gyoergy Lajos; Fetz, Andrea; Schoch, Christian  
 PATENT ASSIGNEE(S): Novartis Ag, Switz.  
 SOURCE: PCT Int. Appl., 22 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

Updated Search

10544224

WO 9710805 A1 19970327 WO 1996-EP3898 19960905  
W: AL, AU, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG  
TW 434023 B 20010516 TW 1996-85101497 19960207  
AU 9669871 A 19970409 AU 1996-69871 19960905  
AU 704925 B2 19990506  
EP 862414 A1 19980909 EP 1996-931025 19960905  
EP 862414 B1 20011205  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI  
CN 1196676 A 19981021 CN 1996-197051 19960905  
CN 1092954 B 20021023  
JP 11512445 T 19991026 JP 1996-512352 19960905  
HU 9900361 A2 19991028 HU 1999-361 19960905  
HU 9900361 A3 19991129  
HU 224353 B1 20050829  
AT 209896 T 20011215 AT 1996-931025 19960905  
PT 862414 T 20020531 PT 1996-931025 19960905  
ES 2169262 T3 20020701 ES 1996-931025 19960905  
CZ 291891 B6 20030618 CZ 1998-800 19960905  
PL 185661 B1 20030630 PL 1996-324921 19960905  
ZA 9607827 A 19970318 ZA 1996-7827 19960917  
HK 1016510 A1 20030606 HK 1999-101735 19990421  
PRIORITY APPLN. INFO.: EP 1995-810575 A 19950918  
WO 1996-EP3898 W 19960905  
AB The present invention describes a pharmaceutical composition, in particular a preserved ophthalmic composition, comprising a cyclodextrin, a quaternary ammonium salt, an alkylene glycol and a drug. Thus, eye drop formulations contained diclofenac potassium 1.00, Tylopxapol 1.00, tromethamine 1.00, propylene glycol 19.0, hydroxypropyl  $\gamma$ -cyclodextrin 20.0, disodium edetate 1.00, and benzalkonium chloride 0.05 mg, 1N HCl qs, and water for injections 1.00 mL.  
IT 15307-86-5, Diclofenac  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ophthalmic compns. containing cyclodextrins and quaternary ammonium compds.)  
RN 15307-86-5 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 13:39:35 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 14 MAR 2007

Updated Search

10544224

L1 E DICLOFENAC/CN  
1 S E3

FILE 'HCAPLUS' ENTERED AT 13:39:57 ON 14 MAR 2007

L2 4481 S L1

L3 519 S L2 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:40:17 ON 14 MAR 2007

L4 E CETYLPYRIDINIUM/CN  
1 S E3

FILE 'HCAPLUS' ENTERED AT 13:40:44 ON 14 MAR 2007

L5 1 S L4 AND L1

L6 4481 S L1

L7 920 S L4

L8 1 S L6 AND L7

L9 20 S L1 AND CETYLPYRIDINIUM?

L10 10 S L9 AND SALT?

=> s l1 () salt?

4481 L1

1204558 SALT?

L11 2 L1 (W) SALT?

=> d l11, ibib abs hitstr, 1-2

L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:69095 HCAPLUS

DOCUMENT NUMBER: 114:69095

TITLE: Stabilized aqueous solutions of pharmaceutically  
acceptable salts of ortho-(2,6-dichlorophenyl)-  
aminophenylacetic acid (diclofenac) for ophthalmic use

INVENTOR(S): Nagy, Ingrid E.

PATENT ASSIGNEE(S): Ciba-Geigy Corp., USA

SOURCE: U.S., 4 pp. Cont. of U.S. Ser. No. 244,547, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4960799	A	19901002	US 1989-333772	19890405
PRIORITY APPLN. INFO.:			US 1986-945702	B1 19861223
			US 1988-166795	B1 19880303
			US 1988-244547	B1 19880913

AB The title solns. (pH 7.0-7.8) comprise per mL solution ortho-(2,6-dichlorophenyl)aminophenylacetic acid (I) salt .apprx.0.1-5.0, EDTA salt .apprx.0.1-10, bacteriostat .apprx.0.01-5, solubilizer .apprx.0.5-200 mg, and the rest H2O. Thus, a solution was prepared from ethoxylated castor oil 100.0, boric acid 38.0, tromethamine 12.0, 2Na EDTA 2.0, thimerosal 0.08, Na I 2.00 g, and H2O to 2 L.

IT 15307-86-5D, salts

RL: BIOL (Biological study)


(ophthalmic solns. containing, stable aqueous)

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)

Updated Search

10544224




L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1984:577517 HCAPLUS  
 DOCUMENT NUMBER: 101:177517  
 TITLE: Resinate of a substituted carboxylic acid and its pharmaceutical use  
 INVENTOR(S): Khanna, Satish Chandra  
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G. , Switz.  
 SOURCE: Ger. Offen., 15 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3400491	A1	19840712	DE 1984-3400491	19840109
DE 3400491	C2	19881110		
CH 655507	A5	19860430	CH 1983-147	19830112
AT 8400007	A	19900415	AT 1984-7	19840102
AT 391467	B	19901010		
GB 2134529	A	19840815	GB 1984-251	19840106
GB 2134529	B	19860924		
EP 122219	A2	19841017	EP 1984-810008	19840106
EP 122219	A3	19850508		
EP 122219	B1	19880921		
R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
US 4510128	A	19850409	US 1984-568976	19840106
AT 37378	T	19881015	AT 1984-810008	19840106
FI 8400069	A	19840713	FI 1984-69	19840109
FI 82682	B	19901231		
FI 82682	C	19910410		
RO 88481	B3	19860130	RO 1984-113260	19840109
CS 269954	B2	19900514	CS 1984-178	19840109
SE 8400098	A	19840713	SE 1984-98	19840110
SE 457959	B	19890213		
SE 457959	C	19890608		
FR 2542735	A1	19840921	FR 1984-288	19840110
FR 2542735	B1	19860418		
DD 218373	A5	19850206	DD 1984-259312	19840110
ES 528770	A1	19850501	ES 1984-528770	19840110
CA 1218077	A1	19870217	CA 1984-445018	19840110
PL 142737	B1	19871130	PL 1984-245656	19840110
BE 898649	A1	19840711	BE 1984-212185	19840111
DK 8400118	A	19840713	DK 1984-118	19840111
DK 166683	B1	19930628		
NO 8400090	A	19840713	NO 1984-90	19840111
NO 162862	B	19891120		
NO 162862	C	19900228		

Updated Search

10544224

AU 8423230	A	19840719	AU 1984-23230	19840111
AU 570230	B2	19880310		
NL 8400098	A	19840801	NL 1984-98	19840111
JP 59134759	A	19840802	JP 1984-2106	19840111
JP 02057058	B	19901203		
ZA 8400212	A	19840829	ZA 1984-212	19840111
HU 34151	A2	19850228	HU 1984-73	19840111
HU 190750	B	19861028		
IL 70660	A	19870831	IL 1984-70660	19840111
PRIORITY APPLN. INFO.:			CH 1983-147	A 19830112
			EP 1984-810008	A 19840106
OTHER SOURCE(S):	MARPAT 101:177517			
GI				




AB Salts of strongly basic anion exchangers (divinylbenzene-styrene copolymer quaternary ammonium derivs.) with diclofenac (I) are useful as anti-inflammatory agents and analgesics showing quick-slow release effects. Thus, 100 g cholestyramine resin (Duolite 143, particle size 80  $\mu$ ) was stirred with 500 mL 2N NaOH at 50° for 4 h, decanted, washed, stirred with 500 mL 2N HCl at 50° for 4 h, decanted, washed, left in iso-PrOH for 2 h, filtered, washed, and dried at 50° in vacuo. This resin (100 g) was added slowly to 100 g I Na salt in 5 L H<sub>2</sub>O, stirred at 50° for 12 h, filtered, and dried at 50° in vacuo. The product was formulated in tablets, capsules, and suppositories.

IT 15307-86-5DP, salts with anion exchangers  
 RL: PREP (Preparation)  
 (preparation of, as inflammation inhibitors and analgesics, with quick-slow release effect)

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



=> file caold  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
84.11	101.62

Updated Search

10544224

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.14	-10.14

FILE 'CAOLD' ENTERED AT 13:44:16 ON 14 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 13:39:35 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 14 MAR 2007  
E DICLOFENAC/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:39:57 ON 14 MAR 2007

L2 4481 S L1

L3 519 S L2 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:40:17 ON 14 MAR 2007

E CETYLPYRIDINIUM/CN

L4 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:40:44 ON 14 MAR 2007

L5 1 S L4 AND L1

L6 4481 S L1

L7 920 S L4

L8 1 S L6 AND L7

L9 20 S L1 AND CETYLPYRIDINIUM?

L10 10 S L9 AND SALT?

L11 2 S L1 () SALT?

FILE 'CAOLD' ENTERED AT 13:44:16 ON 14 MAR 2007

=> s l1 and cetylpyridinium?

0 L1

21 CETYLPYRIDINIUM?

L12 0 L1 AND CETYLPYRIDINIUM?

=> s l1 and salt?

Updated Search

10544224

0 L1  
45526 SALT?  
L13 0 L1 AND SALT?

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	4.29	105.91
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-10.14

FILE 'REGISTRY' ENTERED AT 13:44:38 ON 14 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6  
DICTIONARY FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>  
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\l2l2q.str

L14 STRUCTURE UPLOADED

=> s l14  
SAMPLE SEARCH INITIATED 13:46:36 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 5401 TO ITERATE

37.0% PROCESSED	2000 ITERATIONS	32 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)		
SEARCH TIME: 00.00.01		

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**
	BATCH	**COMPLETE**
PROJECTED ITERATIONS:	103614 TO	112426
PROJECTED ANSWERS:	1171 TO	2285

L15 32 SEA SSS SAM L14

=> s l14 full

Updated Search

10544224

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 13:46:44 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 108906 TO ITERATE

100.0% PROCESSED 108906 ITERATIONS 1099 ANSWERS  
SEARCH TIME: 00.00.01

L16 1099 SEA SSS FUL L14

=> file hcaplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
173.45	279.36

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-10.14

CA SUBSCRIBER PRICE

FILE 'HCAPLUS' ENTERED AT 13:46:47 ON 14 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Mar 2007 VOL 146 ISS 12  
FILE LAST UPDATED: 13 Mar 2007 (20070313/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l16 and cetylpyridinium?

7161 L16

6460 CETYLPYRIDINIUM?

L17 30 L16 AND CETYLPYRIDINIUM?

=> s l17 () salt?

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'L17 (W) SALT?'

1204558 SALT?

L18 14 L17 (W) SALT?

=> d l18, ibib abs hitstr, 1-14

L18 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2006:443573 HCAPLUS  
DOCUMENT NUMBER: 144:475020

Updated Search

10544224

TITLE: Device and method for delivering an oral care agent  
form a hydrophilic polymer layer  
INVENTOR(S): Faasse, Adrian L.; Klemm, Steven Richard; Groeneweg,  
Glen Edward; Thelen, Alan Gene  
PATENT ASSIGNEE(S): Ranir/Dcp Corporation, USA  
SOURCE: U.S. Pat. Appl. Publ., 24 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006099550	A1	20060511	US 2004-985709	20041110
WO 2006052593	A2	20060518	WO 2005-US39632	20051102
WO 2006052593	A3	20070104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-985709 A 20041110

AB A delivery device for oral care agent, especially a tooth whitening agent, is provided which comprises a permanently deformable waxy backing layer, an oral care layer made of a hydrophilic polymer, and a non-woven binding material with a first part that is substantially invested in the oral care layer and a second part that is substantially invested in the backing layer. The device is sized to fit over a plurality of teeth in an upper or lower dental arch of a subject. The oral care layer comprises at least one oral care agent and at least one hydrophilic polymer. When hydrated, the oral care layer has an adhesiveness relative to the surface of a user's teeth that is sufficient to retain the device on the user's teeth when placed thereon. The device can also have an oral care agent which is activated on hydration of the oral care layer, or an oral care layer which releases the oral care agent over time. For example, a system for delivering a tooth whitening agent was constructed comprising (i) a backing layer (thickness of about 0.38 mm) composed of microcryst. wax 50%, paraffin wax 15% and a hydrocarbon resin (Escorez 5380) 35%, (ii) a non-woven binding layer (thickness of about 0.152 mm) composed of a layer of spun bonded polypropylene (Tyvar) invested in the backing layer, and (iii) an oral care layer containing Kollidone 90 58%, Carbowax 400 30%, and Eudragit L100/55 12%. The oral care agent (an aqueous hydrogen peroxide solution

equivalent to 3-10% of oral care layer) was absorbed by the oral care layer, Delnet nonwoven polyolefin fabric scrim was placed over the aqueous hydrogen peroxide solution printed onto the nonwoven, followed by laminating the oral care layer to the binding material. After the backing and oral care layers were formed with the binding material, devices of were cut to the desired size and shape and vacuum formed on a forming die. The overall thickness of the device was about 0.51 to 0.61 mm.

IT 15307-79-6, Diclofenac sodium 15307-86-5, Diclofenac


Updated Search

10544224

RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(multilayered device for delivering oral care agents form hydrophilic polymer layer)

RN 15307-79-6 HCAPLUS


CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



L18 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:472002 HCAPLUS

DOCUMENT NUMBER: 143:13359

TITLE: Nanoparticle compositions comprising antibodies for targeted delivery

INVENTOR(S): Liversidge, Elaine; Cunningham, James

PATENT ASSIGNEE(S): Elan Pharma International Ltd., Ire.

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049091	A2	20050602	WO 2004-US37246	20041109
WO 2005049091	A3	20061109		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

Updated Search

10544224

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG

US 2005147664 A1 20050707 US 2004-979792 20041103  
CA 2545856 A1 20050602 CA 2004-2545856 20041109  
EP 1689442 A2 20060816 EP 2004-810555 20041109

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,  
HR, IS, YU


PRIORITY APPLN. INFO.: US 2003-519251P P 20031113  
WO 2004-US37246 W 20041109

AB The present invention is directed to compns. of one or more  
nanoparticulate active agents, at least one PEG-derivatized surface  
stabilizer, and at least one antibody or fragment thereof, and methods of  
using such compns. for targeting delivery of the one or more active agents  
to a desired site. The one or more active agents preferably have a  
particle size of  $\leq 2 \mu$ . The targeted delivery can be used, e.g.,  
for disease diagnosis, imaging, or drug delivery. Thud, WIN-68209  
particles wee stabilized by PEG-DSPE stabilizer.

IT 15307-86-5, Diclofenac 220991-20-8, Lumiracoxib  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nanoparticle compns. comprising antibodies for targeted delivery)


RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



RN 220991-20-8 HCAPLUS

CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (CA  
INDEX NAME)



L18 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:696335 HCAPLUS

DOCUMENT NUMBER: 141:212762

TITLE: Pharmaceutical compositions containing  
cetylpyridinium salt of diclofenac

INVENTOR(S): Pifferi, Giorgio

PATENT ASSIGNEE(S): Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.  
S.P.A., Italy


SOURCE: PCT Int. Appl., 15 pp.

Updated Search

10544224

DOCUMENT TYPE: CODEN: PIXXD2  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: English  
 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072017	A1	20040826	WO 2004-EP1412	20040212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004212154	A1	20040826	AU 2004-212154	20040212
CA 2511900	A1	20040826	CA 2004-2511900	20040212
EP 1592657	A1	20051109	EP 2004-710394	20040212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1745061	A	20060308	CN 2004-80003068	20040212
JP 2006517565	T	20060727	JP 2006-501845	20040212
US 2006142353	A1	20060629	US 2005-544224	20050802
PRIORITY APPLN. INFO.:			IT 2003-MI269	A 20030214
			WO 2004-EP1412	W 20040212
AB	A cetylpyridinium salt of diclofenac is described. A solution of cetylpyridinium chloride monohydrate with sodium diclofenac to give diclofenac cetylpyridinium salt. A gel/suspension contained cetylpyridinium salt 1.00, and water 4.00 g.			
IT	15307-79-6, Sodium diclofenac RL: RCT (Reactant); RACT (Reactant or reagent) (pharmaceutical comps. containing cetylpyridinium salt of diclofenac)			
RN	15307-79-6 HCAPIUS			
CN	Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)			



10544224

IT 744221-35-OP  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (pharmaceutical comps. containing cetylpyridinium salt of diclofenac)


Updated Search

10544224

RN 744221-35-0 HCAPLUS  
CN Pyridinium, 1-hexadecyl-, salt with 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 86522-08-9  
CMF C14 H10 Cl2 N O2



CM 2

CRN 7773-52-6  
CMF C21 H38 N




L18 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:283883 HCAPLUS  
DOCUMENT NUMBER: 141:184276  
TITLE: Determination of hydrophobic organic salts  
by pseudo-single-phase ion-pair titration in an  
emulsion medium  
AUTHOR(S): Kulichenko, S. A.; Shevchenko, G. M.  
CORPORATE SOURCE: Department of Chemistry, Shevchenko National  
University, Kiev, 01033, Ukraine  
SOURCE: Journal of Analytical Chemistry (Translation of  
Zhurnal Analiticheskoi Khimii) (2004), 59(4), 392-396  
CODEN: JACTE2; ISSN: 1061-9348  
PUBLISHER: MAIK Nauka/Interperiodica Publishing  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Hydrophobic organic salts can be determined by pseudo-single-phase  
ion-par titration in an oil-in-water emulsion stabilized with a nonionic  
surfactant. Conditions were proposed for determining anionic and cationic  
surfactants and some hydrophobic salt pharmaceuticals in an  
emulsion stabilized with Triton X-305 using molybdenum(VI)-pyrogallol  
(bromopyrogallol) red complexes for the detection of the titration end-point.  
IT 15307-79-6, Diclofenac sodium  
RL: ANT (Analyte); ANST (Analytical study)  
(determination of hydrophobic organic salts by pseudo-single-phase  
ion-pair titration in emulsion medium)  
RN 15307-79-6 HCAPLUS

Updated Search

10544224

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA  
INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:120587 HCAPLUS

DOCUMENT NUMBER: 140:157476

TITLE: Use of a compound in providing refreshedness on waking  
and a method for the treatment of grogginess therewith

INVENTOR(S): Sunderraj, Palaniswamy; Jones, Huw; Shephard, Adrian

PATENT ASSIGNEE(S): The Boots Company Plc, UK

SOURCE: U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S.  
Ser. No. 305,354.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004029927	A1	20040212	US 2003-448455	20030530
US 2003134878	A1	20030717	US 2002-305354	20021127
GB 2383537	A	20030702	GB 2002-28045	20021202
GB 2383537	B	20031210		
CN 1617723	A	20050518	CN 2002-827625	20021202
ZA 2004004172	A	20050901	ZA 2004-4172	20040527
US 2007015800	A1	20070118	US 2005-303019	20051216
PRIORITY APPLN. INFO.:			GB 2001-28674	A 20011130
			US 2002-305354	A2 20021127

AB There is disclosed the use of triprolidine for enabling an individual to wake refreshed after sleep and the method of treating such an individual with triprolidine. The triprolidine is administered shortly before a person wishes to fall asleep, preferably orally and most commonly in the form of a tablet containing less than 5 mg, e.g. 0.1 mg, 1.25 mg or 2.5 mg, of the active ingredient. The triprolidine is also effective in enabling an individual to sleep more easily. There is also disclosed such uses of, and methods of treating with, consumable films comprising triprolidine, and triprolidine in combination with at least one further active pharmaceutical agent, and consumable films comprising triprolidine in combination with at least one further active pharmaceutical agent.

IT 15307-86-5, Diclofenac 15307-86-5D, Diclofenac,  
salts or hydrates 89796-99-6, Aceclofenac

Updated Search

10544224

89796-99-6D, Aceclofenac, salts or hydrates


RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as further active agent; triprolidine and compns. in providing  
refreshedness on waking and in treatment of grogginess)


RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)




RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)




RN 89796-99-6 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, carboxymethyl ester  
(9CI) (CA INDEX NAME)



RN 89796-99-6 HCAPLUS


CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, carboxymethyl ester  
(9CI) (CA INDEX NAME)



Updated Search

10544224

IT 15307-79-6, Diclofenac Sodium  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(triprolidine and compns. in providing refreshedness on waking and in  
treatment of grogginess)  
RN 15307-79-6 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA  
INDEX NAME)



● Na

L18 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:11043 HCAPLUS  
DOCUMENT NUMBER: 140:82330  
TITLE: Body protection article having a gelatinous material  
with a therapeutic additive  
INVENTOR(S): Gould, Robert L.; Whelan, Ian Peter  
PATENT ASSIGNEE(S): Silipos Inc., USA  
SOURCE: U.S., 11 pp., Cont.-in-part of U.S. 6,117,119.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6673054	B1	20040106	US 2000-654581	20000901
US 6117119	A	20000912	US 1998-143282	19980828


PRIORITY APPLN. INFO.: US 1998-143282 A2 19980828

AB The present invention is directed to a vitamin additive such as Vitamin A, B12, C, D, E, incorporated into the thermoplastic material of a sock, glove or like body protection article. The thermoplastic material is preferably a block copolymer such as SEBS, SEPS and SEEPS copolymer. Addnl., the thermoplastic material can include natural oils such as grape seed oil, avocado oil, jojoba oil, canola oil, ceramides, aloe and olive oil. Such materials impart beneficial properties to the skin including reducing scar tissue from burned skin and skin healing from a surgical procedure by maintaining the skin in a moist and lubricated state.

IT 15307-86-5, Diclofenac  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(body protection article consisting of gelatinous material with  
therapeutic additive)  
RN 15307-86-5 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)

Updated Search

10544224




REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:42092 HCAPLUS  
DOCUMENT NUMBER: 138:112443  
TITLE: Tablet compositions for poorly-compressible pharmaceuticals  
INVENTOR(S): Matharu, Amol Singh; Patel, Mahendra R.  
PATENT ASSIGNEE(S): Geneva Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 20 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004009	A1	20030116	WO 2002-US20323	20020627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003021841	A1	20030130	US 2002-183881	20020627
PRIORITY APPLN. INFO.:		US 2001-302613P P 20010702		
AB The present invention relates to a process for preparing tablet dosage forms of poorly-compressible pharmaceuticals and to tablet dosage forms. The process is especially useful for preparing tablets of the poorly-compressible drug metformin-HCl. Thus, tablets contained metformin-HCl 500, HPMC 320, stearyl alc. 200, and Mg stearate mg/unit.				
IT 15307-86-5, Diclofenac				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (tablet comps. for poorly-compressible pharmaceuticals)				
RN 15307-86-5 HCAPLUS				
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)				

10544224



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:1215 HCAPLUS

DOCUMENT NUMBER: 138:61315

TITLE: Controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers

INVENTOR(S): Chhabra, Harinderpal; Sarkar, Shyamal K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 23 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6500459	B1	20021231	US 1999-358732	19990721
CA 2314298	A1	20010121	CA 2000-2314298	20000721

PRIORITY APPLN. INFO.: US 1999-358732 A 19990721

AB A pharmaceutical composition for controlled onset and sustained release of an active ingredient, comprises: (i) a core comprising: (a) an active ingredient; (b) a hydrophilic carrier; (c) a hydrodynamic diffusion enhancer; and optionally (d) conventional excipients selected from the group consisting of binders, fillers and lubricants and combinations thereof; and (ii) a functional coating membrane surrounding the core. Thus, 240 g verapamil-HCl was sieved through a mesh sieve and blended with 150 g E50 premium HPMC. To this blend was added 270.0 g croscarmellose sodium and mixed for 15 min. This blend was granulated with PVP K-29/32 solution in iso-PrOH (30% weight/weight). The wet mass obtained in the above

step

was dried at 60° for 3 h. After drying, the granules were passed a mesh sieve. The granules were then mixed with 2.5 g of Magnesium Stearate and 15 g of Stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. The granules were then mixed with 2.5 g of Mg stearate and 15 g of stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. These tablets were then coated by using a perforated coating pan. A seal coating membrane was applied on the surface of tablets to achieve a weight gain of 1.66% of the weight of the core. The seal coating dispersion of Opadry Clear in water at 10% was sprayed on to the surface of the tablets by using a perforated coating pan.

IT 15307-86-5, Diclofenac


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)

RN 15307-86-5 HCAPLUS

Updated Search

10544224

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2002:429542 HCAPLUS  
DOCUMENT NUMBER: 137:11003  
TITLE: Chondroprotective/restorative compositions containing hyaluronic acid  
INVENTOR(S): Pierce, Scott W.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 14 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002068718	A1	20020606	US 2001-967977	20011002
US 6924273	B2	20050802		
US 2005182022	A1	20050818	US 2005-95632	20050401
PRIORITY APPLN. INFO.:			US 2000-237838P	P 20001003
			US 2001-967977	A1 20011002

AB An oral composition based on hyaluronic acid or its salts and optionally a therapeutic drug is provided for treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post-operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, and the reduction or inhibition of the production of hyaluronic acid in a mammal. Addnl., compns. containing hyaluronic acid, chondroitin sulfate and glucosamine sulfate in a paste formulation are also described which can be administered on their own or can be used as a feed additive for cats and dogs. For example, a composition contained (by weight) glucosamine sulfate


36%, chondroitin sulfate 4%, sodium hyaluronate 0.144%, manganese sulfate 0.144%, ibuprofen 200 mg, powdered sugar 20%, glycerin 0.7%, xanthan gum 0.2%, sodium benzoate 0.7%, citric acid 0.2%, molasses 23.5%, and water 14.4%.

IT 15307-79-6, Diclofenac sodium  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chondroprotective/restorative compns. containing hyaluronic acid for treatment of joint disorders)

RN 15307-79-6 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)

Updated Search



● Na

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:31308 HCAPLUS

DOCUMENT NUMBER: 134:91147

TITLE: A method for the improvement of transport across adaptable semi-permeable barriers

INVENTOR(S): Cevc, Gregor

PATENT ASSIGNEE(S): Idea Innovative Dermale Applikationen G.m.b.H., Germany

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001962	A1	20010111	WO 1999-EP4659	19990705
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9954096	A	20010122	AU 1999-54096	19990705
CA 2375157	A1	20010111	CA 2000-2375157	20000705
WO 2001001963	A1	20010111	WO 2000-EP6367	20000705
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1189598	A1	20020327	EP 2000-947939	20000705
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

10544224


HU 200201454	A2	20021228	HU 2002-1454	20000705
JP 2003503442	T	20030128	JP 2001-507458	20000705
EE 200200008	A	20030415	EE 2002-8	20000705
AU 779765	B2	20050210	AU 2000-61557	20000705
RU 2260445	C2	20050920	RU 2002-101651	20000705
HR 2001000881	A1	20030831	HR 2001-881	20011127
IN 2001DN01133	A	20050311	IN 2001-DN1133	20011206
NO 2002000032	A	20020305	NO 2002-32	20020104
US 2003099694	A1	20030529	US 2002-37480	20020104
US 2005123897	A1	20050609	US 2004-984450	20041108
PRIORITY APPLN. INFO.:			WO 1999-EP4659	A 19990705
			WO 2000-EP6367	W 20000705
			US 2002-37480	A1 20020104

AB The invention relates to a method, a kit and a device for controlling the flux of penetrants across an adaptable semi-permeable porous barrier, the method comprising the steps of: preparing a formulation by suspending or dispersing said penetrants in a polar liquid in the form of fluid droplets surrounded by a membrane-like coating of one or several layers, said coating comprising at least two kinds of forms of amphiphilic substances with a tendency to aggregate; said penetrants being able to transport agents through the pores of said barrier or to enable agent permeation through the pores of said barrier after penetrants have entered the pores, selecting a dose amount of said penetrants to be applied on a predetd. area of said barrier to control the flux of said penetrants across said barrier, and applying the selected dose amount of said formulation containing said penetrants onto said area of said porous barrier. Highly adaptable complex droplets (ultradeformable vesicles or Transfersomes) were prepared containing soybean phosphatidylcholine, Na cholate, 3H-labeled DPPC and phosphate buffer.

IT 15307-86-5, Diclofenac  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (improvement of transport across adaptable semi-permeable barriers)

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:456858 HCAPLUS

DOCUMENT NUMBER: 133:94512

TITLE: Improved formulation for topical non-invasive application in vivo

INVENTOR(S): Cevc, Gregor

PATENT ASSIGNEE(S): Idea Innovative Dermale Applikationen G.m.b.H., Germany

SOURCE: PCT Int. Appl., 73 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

Updated Search


10544224

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038653	A1	20000706	WO 1998-EP8421	19981223
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356080	A1	20000706	CA 1998-2356080	19981223
AU 9925137	A	20000731	AU 1999-25137	19981223
AU 770803	B2	20040304		
EP 1140021	A1	20011010	EP 1998-966846	19981223
EP 1140021	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9816113	A	20011023	BR 1998-16113	19981223
JP 2002533379	T	20021008	JP 2000-590607	19981223
EE 200100342	A	20021015	EE 2001-342	19981223
RU 2207844	C2	20030710	RU 2001-120008	19981223
AT 272391	T	20040815	AT 1998-966846	19981223
ES 2226203	T3	20050316	ES 1998-966846	19981223
HR 2001000309	A1	20020630	HR 2001-309	20010502
HR 20010309	B1	20050630		
NO 2001003164	A	20010822	NO 2001-3164	20010622
US 2002064524	A1	20020530	US 2001-887493	20010622
US 7175850	B2	20070213		
HK 1040629	A1	20050128	HK 2002-102230	20020323
PRIORITY APPLN. INFO.:			WO 1998-EP8421	A 19981223
OTHER SOURCE(S):	MARPAT 133:94512			
AB	A formulation comprises mol. arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of the pores is smaller than the average penetrant diameter, provided that			
	the penetrants can transport agents or cause permeation through the pores after penetrants have entered pores. The formulation comprises at least 1 consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over is enabled. The formulation also contains 1 antioxidant in an amount that reduces the increase of oxidation index to <100% per 6 mo and/or at least 1 microbicide in an amount that reduces the bacterial count of 1 million germs added/g of total mass of the formulation to <100 in the case of aerobic bacteria, to <10 in the case of entero-bacteria, and to <1 in the case of Pseudomonas aeruginosa or Staphilococcus aureus, after a period of 4 days. Thus, a composition contained soybean phosphatidylcholine 347, Tween-80 623, sodium dodecyl sulfate 30, benzyl alc. 50, clobetasol 17-propionate 25 and pH 6.5 50 mM phosphate buffer 9000 mg.			
IT	15307-86-5, Diclofenac			
	RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(penetrating formulation for topical non-invasive application in vivo)			
RN	15307-86-5 HCAPLUS			
CN	Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)			

Updated Search

10544224



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:220011 HCAPLUS

DOCUMENT NUMBER: 130:242335

TITLE: High-viscosity liquid controlled-delivery system

INVENTOR(S): Tipton, Arthur J.

PATENT ASSIGNEE(S): Southern Biosystems, Inc., USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913913	A2	19990325	WO 1998-US18629	19980908
WO 9913913	A3	19990603		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2303442	A1	19990325	CA 1998-2303442	19980908
AU 9894750	A	19990405	AU 1998-94750	19980908
EP 1015032	A2	20000705	EP 1998-948113	19980908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9812313	A	20000912	BR 1998-12313	19980908
JP 2001516728	T	20011002	JP 2000-511528	19980908
NZ 503366	A	20050225	NZ 1998-503366	19980908
AU 2006203112	A1	20060810	AU 2006-203112	20060720
PRIORITY APPLN. INFO.:				
			US 1997-944022	A 19970915
			WO 1998-US18629	W 19980908
			AU 2003-200423	A3 20030207

AB A composition for controlled delivery of a biol. active substance for medical or agricultural use includes (a) a nonpolymeric, non-water-soluble liquid carrier material of viscosity  $\geq 5000$  cP at  $37^\circ$  that does not crystallize neat under ambient or physiol. conditions and, optionally, (b) an active substance to be delivered. Prior to application, the high-viscosity carrier (which is preferably biodegradable) is mixed with a viscosity-lowering water-soluble or -miscible solvent to form a lower-viscosity liquid carrier which is mixed with the active substance; on application into the body or on a surface, the solvent dissipates or diffuses away, forming in situ a highly viscous implant or composition that

Updated Search

10544224

releases the active substance over time. The composition may be combined with a 2nd carrier to form an emulsion, gel, or transdermal delivery system. Thus, a composition containing diclofenac Na 2.5, sucrose acetate isobutyrate (high-viscosity carrier) 88, sucrose 2.5, and EtOH 7 weight% released diclofenac into phosphate-buffered saline at 37° to the extent of .apprx.37, 46, and 50% after 1, 24, and 72 h, resp.


IT 15307-79-6, Diclofenac sodium

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(high-viscosity liquid controlled-delivery system)

RN 15307-79-6 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

L18 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:172578 HCAPLUS

DOCUMENT NUMBER: 130:227723

TITLE: In situ formation of bioadhesive polymeric material

INVENTOR(S): Dettmar, Peter William; Jolliffe, Ian Gordon; Skaugrud, Oyvind

PATENT ASSIGNEE(S): Reckitt & Colman Products Limited, UK

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909962	A1	19990304	WO 1998-GB2410	19980810
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2328443	A	19990224	GB 1998-17093	19980807
GB 2328443	B	20010905		
CA 2301165	A1	19990304	CA 1998-2301165	19980810
CA 2301165	C	20070109		

Updated Search

10544224

AU 9887389	A	19990316	AU 1998-87389	19980810
AU 737714	B2	20010830		
EP 1007015	A1	20000614	EP 1998-938785	19980810
EP 1007015	B1	20030709		
R: AT, CH, DE, ES, FR, GB, GR, IT, LI, SE				
BR 9811245	A	20000718	BR 1998-11245	19980810
HU 200003602	A2	20010328	HU 2000-3602	19980810
JP 2001513549	T	20010904	JP 2000-507353	19980810
AT 244562	T	20030715	AT 1998-938785	19980810
ES 2198062	T3	20040116	ES 1998-938785	19980810
PL 192463	B1	20061031	PL 1998-338701	19980810
IN 1998MA01833	A	20050304	IN 1998-MA1833	19980813
ZA 9807516	A	19990222	ZA 1998-7516	19980820
MX 200001818	A	20001026	MX 2000-1818	20000221
US 6391294	B1	20020521	US 2000-485771	20000412

PRIORITY APPLN. INFO.:

GB 1997-17626	A	19970821
GB 1997-17627	A	19970821
WO 1998-GB2410	W	19980810


AB The invention provides a pharmaceutically acceptable polymeric material formed in situ at a body surface and a process for the preparation of material. The polymeric material is formed by applying an anionic polymer and a cationic polymer to the surface in the presence of water. Thus, an anionic solution contained sodium alginate 2, and methylparaben (preservative) 0.1 g, flavors, sweeteners, and colors q.s. and water to 100 mL. A cationic solution contained chitosan chloride (Seacure CL 211) 0.4 and methylparaben (preservative) 0.1 g, flavors, sweeteners, colors q.s. and water to 100 mL. Dissolve the Me paraben, flavors, sweeteners and colors in the water. Between 0.2 and 1 mL of each solution may be sprayed simultaneously onto the back of the throat to form a soothing protective film. This film is of particular benefit to those suffering from a sore throat.

IT 15307-86-5, Diclofenac

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(in situ formation of bioadhesive polymeric material)

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:310769 HCAPLUS

DOCUMENT NUMBER: 126:297668

TITLE: Ophthalmic compositions containing cyclodextrins and quaternary ammonium compounds

INVENTOR(S): Kis, Gyorgy Lajos; Fetz, Andrea; Schoch, Christian

PATENT ASSIGNEE(S): Novartis Ag, Switz.

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

Updated Search


10544224

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9710805	A1	19970327	WO 1996-EP3898	19960905
W: AL, AU, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 434023	B	20010516	TW 1996-85101497	19960207
AU 9669871	A	19970409	AU 1996-69871	19960905
AU 704925	B2	19990506		
EP 862414	A1	19980909	EP 1996-931025	19960905
EP 862414	B1	20011205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1196676	A	19981021	CN 1996-197051	19960905
CN 1092954	B	20021023		
JP 11512445	T	19991026	JP 1996-512352	19960905
HU 9900361	A2	19991028	HU 1999-361	19960905
HU 9900361	A3	19991129		
HU 224353	B1	20050829		
AT 209896	T	20011215	AT 1996-931025	19960905
PT 862414	T	20020531	PT 1996-931025	19960905
ES 2169262	T3	20020701	ES 1996-931025	19960905
CZ 291891	B6	20030618	CZ 1998-800	19960905
PL 185661	B1	20030630	PL 1996-324921	19960905
ZA 9607827	A	19970318	ZA 1996-7827	19960917
HK 1016510	A1	20030606	HK 1999-101735	19990421
PRIORITY APPLN. INFO.:			EP 1995-810575	A 19950918
			WO 1996-EP3898	W 19960905
AB	The present invention describes a pharmaceutical composition, in particular a preserved ophthalmic composition, comprising a cyclodextrin, a quaternary ammonium salt, an alkylene glycol and a drug. Thus, eye drop formulations contained diclofenac potassium 1.00, Tylopxapol 1.00, tromethamine 1.00, propylene glycol 19.0, hydroxypropyl $\gamma$ -cyclodextrin 20.0, disodium edetate 1.00, and benzalkonium chloride 0.05 mg, 1N HCl qs, and water for injections 1.00 mL.			
IT	15307-79-6, Diclofenac sodium 15307-81-0, Diclofenac potassium 15307-86-5, Diclofenac			
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ophthalmic compns. containing cyclodextrins and quaternary ammonium compds.)			
RN	15307-79-6 HCAPLUS			
CN	Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)			


Updated Search

10544224




● Na

RN 15307-81-0 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, potassium salt (1:1)  
(CA INDEX NAME)



● K

RN 15307-86-5 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 13:39:35 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:39:40 ON 14 MAR 2007  
E DICLOFENAC/CN

L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:39:57 ON 14 MAR 2007

L2 4481 S L1

L3 519 S L2 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:40:17 ON 14 MAR 2007  
E CETYLPIRIDINIUM/CN

Updated Search

10544224

L4 1 S E3

FILE 'HCAPLUS' ENTERED AT 13:40:44 ON 14 MAR 2007

L5 1 S L4 AND L1  
L6 4481 S L1  
L7 920 S L4  
L8 1 S L6 AND L7  
L9 20 S L1 AND CETYLPYRIDINIUM?  
L10 10 S L9 AND SALT?  
L11 2 S L1 () SALT?

FILE 'CAOLD' ENTERED AT 13:44:16 ON 14 MAR 2007

L12 0 S L1 AND CETYLPYRIDINIUM?  
L13 0 S L1 AND SALT?

FILE 'REGISTRY' ENTERED AT 13:44:38 ON 14 MAR 2007

L14 STRUCTURE UPLOADED  
L15 32 S L14  
L16 1099 S L14 FULL

FILE 'HCAPLUS' ENTERED AT 13:46:47 ON 14 MAR 2007

L17 30 S L16 AND CETYLPYRIDINIUM?  
L18 14 S L17 () SALT?

=> s l17 not l18

L19 16 L17 NOT L18

=> d l19, ibib abs hitstr, 1-16

L19 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:175482 HCAPLUS

DOCUMENT NUMBER: 146:236130

TITLE: Nanoemulsion compositions having anti-inflammatory activity

INVENTOR(S): Baker, James R.

PATENT ASSIGNEE(S): Nanobio Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 25pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007036831	A1	20070215	US 2006-501007	20060809
PRIORITY APPLN. INFO.:			US 2005-706429P	P 20050809

AB Nanoemulsion compns. with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, at least one anti-inflammatory agent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided. Thus, a nanoemulsion contained EDTA 25, and cetylpyridinium chloride 25 g, EtOH 200, Tween-20 125, soybean oil 1600, and water 548 mL.

IT 15307-79-6, Diclofenac sodium 15307-81-0, Diclofenac potassium 239810-53-8, Arthrotec


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nanoemulsion compns. having anti-inflammatory activity)

Updated Search

10544224

RN 15307-79-6 HCAPLUS


CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 15307-81-0 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 239810-53-8 HCAPLUS


CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11 $\alpha$ ,13E)-, mixt. with 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid monosodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 59122-46-2

CMF C22 H38 O5

Relative stereochemistry.  
Double bond geometry as shown.




Updated Search

10544224

CM 2

CRN 15307-79-6

CMF C14 H11 Cl2 N O2 . Na



● Na

L19 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:100738 HCAPLUS

DOCUMENT NUMBER: 144:198849

TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients

INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar

PATENT ASSIGNEE(S): India

SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006024365	A1	20060202	US 2005-134633	20050519
IN 193042	A1	20040626	IN 2002-MU697	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 2004096499	A1	20040520	US 2003-630446	20030729
PRIORITY APPLN. INFO.:			IN 2002-MU697	A 20020805
			IN 2002-MU699	A 20020805
			IN 2003-MU80	A 20030122
			IN 2003-MU82	A 20030122
			US 2003-630446	A2 20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared. The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

IT 15307-79-6, Diclofenac sodium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


Updated Search

10544224

(novel dosage form comprising modified-release and immediate-release active ingredients)

RN 15307-79-6 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



L19 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1354875 HCAPLUS

DOCUMENT NUMBER: 144:64394

TITLE: Use of a compound in the treatment of sleep disorders

INVENTOR(S): Sunderraj, Palaniswamy; Shephard, Adrian; Jones, Huw

PATENT ASSIGNEE(S): Boots Healthcare International Limited, UK

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123074	A1	20051229	WO 2004-GB2330	20040601
WO 2005123074	A9	20061214		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2524805	A1	20041130	CA 2004-2524805	20040601
AU 2004319510	A1	20060105	AU 2004-319510	20040601
EP 1660082	A1	20060531	EP 2004-735597	20040601
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1842334	A	20061004	CN 2004-80022386	20040601
PRIORITY APPLN. INFO.:			GB 2003-12419	A 20030530
			WO 2004-GB2330	W 20040601
AB	A method is disclosed for the treatment of sleep disorders. The method involves administration of triprolidine, in combination with at least one			

Updated Search

10544224


further active pharmaceutical agent, for enabling an individual to wake refreshed after sleep and the method of treating such an individual with triprolidine. Use of triprolidine, in combination with at least one further active pharmaceutical agent, as active ingredient in the manufacture of a composition for the treatment of sleep disorders is also described. A method of treating sleep of a person suffering from a sleep disorder, which method comprises administration of an ED of triprolidine, in combination with at least one further active pharmaceutical agent, as active ingredient to such a person is also described. The triprolidine is administered shortly before a person wishes to fall asleep, preferably orally and most commonly in the form of a tablet containing up to 20mg, e.g. 0.1mg, 1.25mg or 2.5mg, of the active ingredient. The triprolidine is also effective in enabling an individual to sleep more easily.

IT 15307-79-6, Diclofenac sodium 15307-86-5, Diclofenac  
89796-99-6, Aceclofenac  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(method for treatment of sleep disorders)  
RN 15307-79-6 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA  
INDEX NAME)



● Na


RN 15307-86-5 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



RN 89796-99-6 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, carboxymethyl ester  
(9CI) (CA INDEX NAME)

Updated Search

10544224



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2005:962008 HCAPLUS  
DOCUMENT NUMBER: 143:235523  
TITLE: Pharmaceutical preparation for the oral cavity  
INVENTOR(S): Veronesi, Paulo Alberto  
PATENT ASSIGNEE(S): Therapicon S.r.l., Italy  
SOURCE: PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079747	A1	20050901	WO 2004-EP14478	20041220
WO 2005079747	A8	20060126		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1713439	A1	20061025	EP 2004-804078	20041220
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			

PRIORITY APPLN. INFO.: IT 2004-MI235 A 20040213  
WO 2004-EP14478 W 20041220


AB A pharmaceutical preparation in the form of an aqueous solution comprises: (a)  
a

nonsteroidal anti-inflammatory drug (NSAID) also having analgesic activity, (b) a biol. compatible buffering organic amine provided with a free or monosubstituted amino group or a mixture thereof, in a quantity suitable for buffering the pH of 6.5 to 8.0, and (c) pharmaceutical grade water; wherein the NSAID is flurbiprofen and/or diclofenac; and the biol. compatible buffering organic amine is D-glucamine, meglumine, trometamol (tris buffer) or a mixture thereof. For example, an oral solution contained flurbiprofen 2.5, meglumine (to pH 7.1) 2.1, methylparaben 1, propylparaben 0.2, glycerol 100, sorbitol 70, ethanol 100, ethoxylated hydrogenated castor oil 24, saccharin sodium 1.5, mint essence 6 mg, and purified water to 1 mL.

Updated Search

10544224

IT 15307-86-5, Diclofenac  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oral solns. comprising analgesic NSAID and buffering amines)  
RN 15307-86-5 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:412720 HCAPLUS  
DOCUMENT NUMBER: 140:395547  
TITLE: Medicated comestibles  
INVENTOR(S): Conyers, Leigh  
PATENT ASSIGNEE(S): SSL International PLC, UK  
SOURCE: PCT Int. Appl., 24 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

5/21/2004

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004040992	A1	20040521	WO 2003-GB4823	20031106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003283533	A1	20040607	AU 2003-283533	20031106
PRIORITY APPLN. INFO.:			GB 2002-25827	A 20021106
			WO 2003-GB4823	W 20031106

AB A chewable medicated comestible is made by mixing a pharmaceutically active ingredient, water and a substrate. The substrate has confectionery and binding properties and the mixing process produces a malleable solid confection which can be divided into discrete dosed units in the form of chewable tablets. The substrate may be a particular sugar. A chewable tablet contained modified starch 50, water 7, sorbitol 8, starch 1.5, milk protein 1, gelatin 1.2, water 5, glycerol 5, propylene glycol 2, titanium dioxide 1, vegetable fat 6, omeprazole 0.25, lactose 7.05, and maltodextrin 10%.


IT 15307-86-5, Diclofenac  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medicated comestibles)

Updated Search

10544224

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



L19 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:188882 HCAPLUS

DOCUMENT NUMBER: 140:380621

TITLE: Agent for treatment of allergic rhinitis and allergic conjunctivitis

INVENTOR(S): Gaponyuk, P. Ya.; Markov, I. A.; Markova, E. A.; Gaponyuk, P. P.

PATENT ASSIGNEE(S): Russia

SOURCE: Russ., No pp. given

CODEN: RUXXE7

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2220740	C1	20040110	RU 2002-123273	20020830
PRIORITY APPLN. INFO.:			RU 2002-123273	20020830

AB This invention relates to preparing agent for treatment of allergic rhinitis and allergic conjunctivitis. Agent comprises a base and cytokines taken among the group: recombinant alpha-, beta-, gamma-interferon taken in the amount 1000-100,000 IU/g of agent; antihistaminic preps. taken among the group: diazolin, mebhydrolin, antazoline, ebastin, loratadine, levocabastine, azelastine, astemizole, terfenadine, diphenhydramine, chloropyramine, cetirizine, promethazine taken in the amount 0.0001-0.1 g/g of agent; corticosteroid preps. taken among the group: hydrocortisone, fludrocortisone, flumetasone, betamethasone, mometasone, fluorocortolone, triamcinolone, prednisone, prednisolone, dexamethasone taken in the amount 0.002-0.01 g/g of agent. Agent comprises addnl. anti-inflammatory preps. taken among the group: sodium diclofenac, indometacin, ibuprofen, naproxen; antibacterial agent taken among the group: dioxydine, zinc sulfate, myramistin; antibiotics with broad spectrum of effect, methylbenzethonium chloride, cetylpyridinium chloride, alkyltrimethylammonium bromide, chlorhexidine gluconate, iodopovidone, imidazolidinyl urea, diazolidinyl urea. Agent comprises also addnl. regulators and stabilizers of cellular functions taken among the group: theophylline, sodium cromoglycate, sodium nedocrimal, vitamins and it comprises also vasoconstrictive preps. taken among the group: xylometazoline, naphazoline, oxymetazoline, tetrazyline, phenylephrine. As a base the agent comprises one or some components taken among the group of addns. including: vaseline, glycerol, polyethylene oxide, propylene glycol, vegetable oil, essential oil, silicone oil. Invention provides the development of highly effective agent for treatment of allergic rhinitis and allergic conjunctivitis. The invention showed improved preparation method, enhanced effectiveness and valuable medicinal properties of

Updated Search

10544224

agent.  
 IT 15307-79-6, Sodium diclofenac  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (agent for treatment of allergic rhinitis and allergic conjunctivitis)  
 RN 15307-79-6 HCAPLUS  
 CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA  
 INDEX NAME)



● Na

L19 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2003:511859 HCAPLUS  
 DOCUMENT NUMBER: 139:90459  
 TITLE: Use of an immediate-release powder in pharmaceutical  
 and nutraceutical compositions  
 INVENTOR(S): Besse, Jerome; Besse, Laurence  
 PATENT ASSIGNEE(S): Fr.  
 SOURCE: U.S. Pat. Appl. Publ., 5 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003124191	A1	20030703	US 2002-106923	20020325
FR 2834212	A1	20030704	FR 2001-16934	20011227
FR 2834212	B1	20040709		
CA 2471903	A1	20030710	CA 2002-2471903	20021227
WO 2003055464	A1	20030710	WO 2002-FR4575	20021227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002364489	A1	20030715	AU 2002-364489	20021227
EP 1458356	A1	20040922	EP 2002-799854	20021227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015380	A	20041207	BR 2002-15380	20021227

Updated Search

10544224

US 2005118272 A1 20050602 US 2003-500213 20021227  
 JP 2005520799 T 20050714 JP 2003-556042 20021227  
 HU 200500509 A2 20050928 HU 2005-509 20021227  
 NO 2004003172 A 20040914 NO 2004-3172 20040726  
 PRIORITY APPLN. INFO.: FR 2001-16934 A 20011227  
 WO 2002-FR4575 W 20021227

AB The present invention relates to the use of a powder comprising at least one active substance, at least one surfactant, at least one wetting agent and at least one diluent, for preparing a pharmaceutical or nutraceutical composition, this composition allowing rapid and immediate release of the active substance. Granules containing phloroglucinol 10, sorbitol 89, and propylene glycol 1% were prepared  
 IT 15307-86-5, Diclofenac  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (use of immediate-release powder in pharmaceutical and nutraceutical compns.)  
 RN 15307-86-5 HCAPLUS  
 CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



L19 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2003:154225 HCAPLUS  
 DOCUMENT NUMBER: 138:210299  
 TITLE: Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds  
 INVENTOR(S): Moro, Daniel G.; Callahan, Howard; Nowotnik, David P.  
 PATENT ASSIGNEE(S): Access Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015748	A2	20030227	WO 2002-US26083	20020816
WO 2003015748	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

Updated Search

10544224

US 2003044446	A1	20030306	US 2001-931319	20010816
US 6585997	B2	20030701		
CA 2459692	A1	20030227	CA 2002-2459692	20020816
EP 1418889	A2	20040519	EP 2002-761390	20020816
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
HU 200401281	A2	20041129	HU 2004-1281	20020816
JP 2005504763	T	20050217	JP 2003-520708	20020816
NZ 531766	A	20051223	NZ 2002-531766	20020816
CN 1738599	A	20060222	CN 2002-818327	20020816
ZA 2004002067	A	20050528	ZA 2004-2067	20040315

PRIORITY APPLN. INFO.:


US 2001-931319	A	20010816
WO 2002-US26083	W	20020816

AB The present invention relates to a layered pharmaceutical delivery device for the administration of pharmaceuticals or other active compds. to mucosal surfaces. The device may also be used by itself without the incorporation of a therapeutic. The device of the present invention consists of a water-soluble adhesive layer, a non-adhesive, bioerodible backing layer and one or more pharmaceuticals if desired in either or both layers. Upon application, the device adheres to the mucosal surface, providing protection to the treatment site and localized drug delivery. The "Residence Time", the length of time the device remains on the mucosal surface before complete erosion, can be easily regulated by modifications of the backing layer.

IT 15307-79-6, Diclofenac sodium 15307-86-5, Diclofenac  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (mucoadhesive erodible drug delivery device for controlled  
 administration of pharmaceuticals and other active compds.)

RN 15307-79-6 HCAPLUS


CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



Updated Search

10544224

L19 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:10602 HCAPLUS

DOCUMENT NUMBER: 134:76392

TITLE: Pharmaceutical dosage forms for controlled release  
producing at least a timed pulse

INVENTOR(S): Andre, Frederic; Lewis, Gareth; Mignonneau, Jerome;  
Ribardiere, Agnes

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.

SOURCE: Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1064938	A1	20010103	EP 1999-401606	19990628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2370067	A1	20010104	CA 2000-2370067	20000627
WO 2001000182	A1	20010104	WO 2000-EP6795	20000627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000011999	A	20020305	BR 2000-11999	20000627
EP 1194131	A1	20020410	EP 2000-949361	20000627
EP 1194131	B1	20040901		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103604	T2	20020422	TR 2001-3604	20000627
HU 200202259	A2	20021228	HU 2002-2259	20000627
JP 2003503341	T	20030128	JP 2001-505892	20000627
NZ 515826	A	20040430	NZ 2000-515826	20000627
AT 274902	T	20040915	AT 2000-949361	20000627
PT 1194131	T	20050131	PT 2000-949361	20000627
ES 2225183	T3	20050316	ES 2000-949361	20000627
AU 780769	B2	20050414	AU 2000-62747	20000627
CZ 296067	B6	20060111	CZ 2001-4639	20000627
SK 285359	B6	20061103	SK 2001-1910	20000627
TW 242451	B	20051101	TW 2000-89112859	20000629
ZA 2001009849	A	20021129	ZA 2001-9849	20011129
NO 2001006282	A	20020227	NO 2001-6282	20011220
HK 1043056	A1	20050429	HK 2002-104683	20020624
PRIORITY APPLN. INFO.:			EP 1999-401606	A 19990628
			WO 2000-EP6795	W 20000627

AB The invention relates to delayed release coated cores comprising an active substance in their core and a polymer coating comprising at least one or more ammoniomethacrylate copolymer, characterized in that the core comprises a surfactant and monolithic or multiparticulate pharmaceutical dosage forms comprising such delayed release coated cores. Capsules were prepared containing alfuzosin-HCl beads coated with a HPMC-succinic acid-cetylpyridinium chloride solution and then coated with a composition

Updated Search

10544224

containing Eudragits RS100 and RL100.  
 IT 15307-86-5, Diclofenac  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical dosage forms for controlled release producing at least  
 a timed pulse)  
 RN 15307-86-5 HCAPLUS  
 CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:900422 HCAPLUS  
 DOCUMENT NUMBER: 134:61524  
 TITLE: Controlled-release and taste-masking oral compositions  
 INVENTOR(S): Villa, Roberto; Pedrani, Massimo; Ajani, Mauro;  
 Fossati, Lorenzo  
 PATENT ASSIGNEE(S): Cip-Ninety Two-92 S.A., Panama  
 SOURCE: PCT Int. Appl., 25 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076478	A1	20001221	WO 2000-EP5356	20000609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 99MI1317	A1	20001214	IT 1999-MI1317	19990614
IT 2000MI0422	A1	20010903	IT 2000-MI422	20000303
IT 1317871	B1	20030715		
CA 2377301	A1	20001221	CA 2000-2377301	20000609
EP 1183014	A1	20020306	EP 2000-942044	20000609
EP 1183014	B1	20031008		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
TR 200200562	T2	20020521	TR 2002-562	20000609
JP 2003501457	T	20030114	JP 2001-502812	20000609
AT 251449	T	20031015	AT 2000-942044	20000609
PT 1183014	T	20031231	PT 2000-942044	20000609
ES 2208349	T3	20040616	ES 2000-942044	20000609
RU 2246293	C2	20050220	RU 2002-100367	20000609

Updated Search


10544224

NO 2001006108	A	20020124	NO 2001-6108	20011214
HK 1046244	A1	20050603	HK 2002-107843	20021030
US 2006134208	A1	20060622	US 2005-268500	20051108
US 2006159749	A1	20060720	US 2006-378378	20060320
PRIORITY APPLN. INFO.:			IT 1999-MI1317	A 19990614
			IT 2000-MI422	A 20000303
			WO 2000-EP5356	W 20000609
			US 2001-9532	A2 20011212
			US 2005-262799	A2 20051101

AB This invention relates to controlled release and taste masking comps. containing one or more active principles incorporated in a three-component matrix structure, i.e. a structure formed by amphiphilic, lipophilic or inert matrixes and finally incorporated or dispersed in hydrophilic matrixes. The use of a plurality of systems for the control of the dissoln. of the active ingredient modulates the dissoln. rate of the active ingredient in aqueous and/or biol. fluids, thereby controlling the release kinetics in the gastrointestinal tract. For example, a taste-masked buccal tablet contained ibuprofen 100, cetyl alc. (lipophilic/inert matrix) 15, soy lecithin (amphiphilic matrix) 8, mannitol (hydrophilic matrix) 167, maltodextrin 150, hydroxypropyl Me cellulose 30, aspartame 15, flavors 5, colloidal silica 5, and Mg stearate 5 mg.


IT 15307-79-6, Diclofenac sodium 15307-86-5, Diclofenac  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(multiple matrix system for controlled-release and taste-masking oral comps.)

RN 15307-79-6 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 15307-86-5 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


Updated Search

10544224

L19 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:34731 HCAPLUS  
 DOCUMENT NUMBER: 132:83685  
 TITLE: Chewable oral unit dosages  
 INVENTOR(S): Jolliffe, Ian  
 PATENT ASSIGNEE(S): Reckitt & Colman Products Limited, UK  
 SOURCE: PCT Int. Appl., 17 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001372	A2	20000113	WO 1999-GB1851	19990610
WO 2000001372	A3	20000224		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2338896	A	20000112	GB 1998-14234	19980702
GB 2338896	B	20030521		
AU 9942822	A	20000124	AU 1999-42822	19990610
AU 760637	B2	20030522		
EP 1089717	A2	20010411	EP 1999-959109	19990610
R: DE, ES, FR, GB, IT				
IN 2001CN00073	A	20050304	IN 2001-CN73	20010116
ZA 2001000518	A	20020118	ZA 2001-518	20010118
US 6589551	B1	20030708	US 2001-720349	20010215
PRIORITY APPLN. INFO.:			GB 1998-14234	A 19980702
			WO 1999-GB1851	W 19990610
AB This invention relates to an oral unit dosage comprising a substrate defining a plurality of discrete reservoirs each containing a liquid fill for release in the mouth. Each oral unit dosage comprised a single piece of gelatin defining twelve reservoirs each having a liquid fill (0.1 mL) containing				
CaCO <sub>3</sub> 500, NaHCO <sub>3</sub> 100, fractionated coconut oil 600, lecithin 12, colloidal silica 34, sorbitan fatty esters 34, polysorbate-80 20, and flavors/colors/sweeteners 80 mg per capsule. The resultant chewable capsules delivered an antacid material to the throat and esophagus without the chalky characteristics normally associated with conventional antacid tablets.				
IT 15307-86-5, Diclofenac				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (chewable oral unit dosage for releasing liqs. containing active agents)				
RN 15307-86-5 HCAPLUS				
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)				

10544224



L19 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:468441 HCAPLUS

DOCUMENT NUMBER: 131:92543

TITLE: Sustained release medicinal compositions

INVENTOR(S): Yamashita, Noboru; Takagi, Akira; Katsuma, Masataka; Saito, Katsumi; Takaishi, Yuuki; Yasuda, Tatsuo; Takahashi, Yutaka; Mitomi, Mitsuo

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933491	A1	19990708	WO 1998-JP5916	19981225
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2316485	A1	19990708	CA 1998-2316485	19981225
AU 9916897	A	19990719	AU 1999-16897	19981225
AU 742250	B2	20011220		
EP 1043031	A1	20001011	EP 1998-961564	19981225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
NZ 505163	A	20021126	NZ 1998-505163	19981225
CN 1132632	B	20031231	CN 1998-812692	19981225
US 6328979	B1	20011211	US 2000-582384	20000623
JP 2006111636	A	20060427	JP 2005-373626	20051226

PRIORITY APPLN. INFO.:

JP 1997-360265 A 19971226  
JP.2000-526240 A3 19981225  
WO 1998-JP5916 W 19981225

AB Disclosed are sustained release medicinal compns. of medicinally active ionic substances containing ionic compds. which are charged oppositely to the medicinally active ionic substances (excluding ionic prostanoid acid derivs.) and capable of elevating the hydrophobicity of the above substances. More particularly speaking, the above-mentioned ionic compds. are those each having a hydrophobic group in its mol. These medicinal compns. can exert excellent and long-lasting effects regardless of the water-solubility of the medicinally active ionic substances. A gel contained diclofenac sodium 0.1, benzalkonium chlorides 0.36, HPC-M 10, and water 89.54 %.

IT 15307-79-6, Diclofenac sodium


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sustained release compns. containing ionic active agents and oppositely

Updated Search

10544224

charged compds.)  
RN 15307-79-6 HCAPLUS  
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA  
INDEX NAME).



● Na

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1999:468439 HCAPLUS  
DOCUMENT NUMBER: 131:92541  
TITLE: Sustained release medicinal compositions containing  
ionic prostanoid acid derivatives  
INVENTOR(S): Yamashita, Noboru; Takagi, Akira; Katsuma, Masataka;  
Saito, Katsumi; Takaishi, Yuuki; Yasuda, Tatsuo;  
Takahashi, Yutaka; Mitomi, Mitsuo; Hara, Michio  
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Toray  
Industries, Inc.  
SOURCE: PCT Int. Appl., 40 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933489	A1	19990708	WO 1998-JP5914	19981225
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9916895	A	19990719	AU 1999-16895	19981225
CN 1132632	B	20031231	CN 1998-812692	19981225
JP 2006111636	A	20060427	JP 2005-373626	20051226
PRIORITY APPLN. INFO.:			JP 1997-360265	A 19971226
			JP 2000-526240	A3 19981225
			WO 1998-JP5914	W 19981225
AB	Disclosed are sustained release medicinal compns. of ionic medicinally active substances, which contain ionic compds. oppositely charged with respect to the ionic medicinally active substances and elevating the hydrophobicity of these substances. The ionic compds. are those having			

Updated Search

10544224

hydrophobic group(s) in the mol. These medicinal compns. can exhibit excellent sustained release effects of the ionic medicinally active substances regardless of the solubility of the substances in water. A mixture containing beraprost 0.024, capryldimethylbenzylammonium chloride 0.29, and water 89.686 parts was blended with 10 parts hydroxypropyl cellulose to give a fully swollen gel.


IT 15307-79-6, Diclofenac sodium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sustained release compns. containing ionic active compds. and oppositely charged compds.)

RN 15307-79-6 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:311079 HCAPLUS

DOCUMENT NUMBER: 130:342792

TITLE: Improved personal care formulations containing amphiphilic phospholipid carriers for topical mucosal applications

INVENTOR(S): Luriya, Elena; Luriya, Leonid

PATENT ASSIGNEE(S): Lurident Ltd., Israel

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9922703	A1	19990514	WO 1998-IL504	19981018
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IL 122084	A	19990922	IL 1997-122084	19971031
CA 2307886	A1	19990514	CA 1998-2307886	19981018

Updated Search

10544224


AU 9895587	A	19990524	AU 1998-95587	19981018
AU 758188	B2	20030320		
EP 1027029	A1	20000816	EP 1998-949227	19981018
R: AT, DE, FR, GB, IT, NL				
JP 2001521882	T	20011113	JP 2000-518642	19981018
US 6861060	B1	20050301	US 2000-557098	20000421
PRIORITY APPLN. INFO.:			IL 1997-122084	A 19971031
			WO 1998-IL504	W 19981018

AB Personal care and hygiene formulations for topical application to mucosal surfaces. These formulations include an amphiphilic lipid carrier in the form of a colloidal composition which can include a micellar aggregate or mixed micelles dispersed in a continuous aqueous phase, or an emulsion of lipid droplets suspended in a continuous aqueous phase, and an active agent which is an anti-microbial agent. The lipid carrier has high adhesiveness to mucous membranes such as the soft tissues of the oral cavity. The lipid carrier also has a high load capacity for the active agent to be carried to these tissues. These formulations have the desirable properties of carrying a large amount of active agent for controlled and prolonged release thereof at the desired site, such as mucous membrane surfaces and surrounding tissue. Accordingly, the present invention provides a formulation for oral or topical application including an anti-microbial agent and a lipid. The agent is held by the carrier through a hydrophobic interaction and is released from the carrier in a controlled manner over a prolonged period of time. The lipid is also characterized by having a high adhesive capability towards mucous membrane surfaces. The lipid and the agent are preferably present in a ratio in a range of from about 1:10 to about 10:1, more preferably from about 1:5 to about 5:1, and most preferably from about 1:3 to about 3:1 in the formulation. A mouthwash was formulated from egg lecithin (E-80) 7.5, chlorhexidine diacetate 0.625, Tween-80 0.525, D,L-menthol 0.25,  $\alpha$ -tocopherol 0.03, glycerol 10 g, EtOH 20, propylene glycol 10, and water 480 mL.

IT 15307-86-5, Diclofenac  
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (topical formulations for mucosal applications containing bioactive agents and amphiphilic phospholipid carriers having high adhesive properties to mucosal tissue)

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:116847 HCAPLUS

DOCUMENT NUMBER: 120:116847

TITLE: Biodegradable controlled release melt-spun delivery system

INVENTOR(S): Fuisz, Richard C.

PATENT ASSIGNEE(S): Fuisz Technologies, Ltd., USA

Updated Search

10544224

SOURCE: PCT Int. Appl., 45 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9324154	A1	19931209	WO 1993-US5307	19930602
W: AU, CA, HU, JP, KR, PL, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5518730	A	19960521	US 1992-893238	19920603
AU 9344058	A	19931230	AU 1993-44058	19930602
AU 665844	B2	19960118		
JP 07507548	T	19950824	JP 1994-500877	19930602
EP 746342	A1	19961211	EP 1993-914373	19930602
EP 746342	B1	20020814		
R: BE, CH, DE, DK, FR, GB, IE, IT, LI, LU, NL, SE				
PRIORITY APPLN. INFO.:			US 1992-893238	A2 19920603
			WO 1993-US5307	A 19930602

AB Biodegradable controlled-release delivery systems using melt-spun biodegradable polymers as carriers for bio-effecting agents such as pharmaceutical actives are disclosed. Oral dose forms as well as implants are described. For example, polyglycolide was melt-spun in combination with various drugs such as vancomycin, gentamicin, tolmetin, diphenhydramine, ibuprofen, and insulin and controlled drug release was demonstrated.

IT 15307-79-6, Diclofenac sodium  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled-release pharmaceuticals formed by flash-flow melt-spinning containing, biodegradable polymers as carriers in)

RN 15307-79-6 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)



● Na

L19 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1993:546734 HCAPLUS  
 DOCUMENT NUMBER: 119:146734  
 TITLE: HPLC of antiphlogistic acids on silica dynamically modified with cetylpyridinium chloride  
 AUTHOR(S): Szasz, G.; Budvari-Barany, Z.; Lore, A.; Radeczky, G.; Shalaby, A.  
 CORPORATE SOURCE: Inst. Pharm. Chem., Semmelweis Med. Univ., Budapest,

Updated Search

10544224

SOURCE: Hung.  
Journal of Liquid Chromatography (1993), 16(11),  
2335-45  
CODEN: JLCHD8; ISSN: 0148-3919

DOCUMENT TYPE: Journal


LANGUAGE: English

AB The cetylpyridinium chloride (CPC) which contains an aromatic ring and a hydrophobic cetyl group differs in its structure from the generally used cationic counter ions. Thirteen of antiphlogistic acids and their derivs. were investigated. Silica as a stationary phase and an eluent containing CPC were used. The conclusion can be drawn that CPC functions as an ion pairing agent and its use in the aqueous eluent results in the formation of a dynamically modified silica surface. The adsorption isotherm for CPC on the bare silica also was determined. Comparative data are shown on the retention of several antiphlogistic acids with CPC and cetrinide containing aqueous eluents.

IT 15307-86-5, Diclofenac  
RL: ANT (Analyte); ANST (Analytical study)  
(determination of, by HPLC, cetylpyridinium chloride as ion-pair agent in)

RN 15307-86-5 HCAPLUS

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (CA INDEX NAME)



=> file caold  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
173.70	453.06

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-23.40	-33.54

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 13:50:10 ON 14 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Updated Search

10544224

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Updated Search